Gotowa bibliografia na temat „3CLpro”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „3CLpro”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "3CLpro"
Ziebuhr, John, Sonja Bayer, Jeff A. Cowley i Alexander E. Gorbalenya. "The 3C-Like Proteinase of an Invertebrate Nidovirus Links Coronavirus and Potyvirus Homologs". Journal of Virology 77, nr 2 (15.01.2003): 1415–26. http://dx.doi.org/10.1128/jvi.77.2.1415-1426.2003.
Pełny tekst źródłaTsu, Brian V., Rimjhim Agarwal, Nandan S. Gokhale, Jessie Kulsuptrakul, Andrew P. Ryan, Elizabeth J. Fay, Lennice K. Castro i in. "Host-specific sensing of coronaviruses and picornaviruses by the CARD8 inflammasome". PLOS Biology 21, nr 6 (8.06.2023): e3002144. http://dx.doi.org/10.1371/journal.pbio.3002144.
Pełny tekst źródłaRawson, Jonathan M. O., Alice Duchon, Olga A. Nikolaitchik, Vinay K. Pathak i Wei-Shau Hu. "Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors". Viruses 13, nr 2 (24.01.2021): 173. http://dx.doi.org/10.3390/v13020173.
Pełny tekst źródłaZhang, Jingjing, Yingpei Jiang, Chunxiu Wu, Dan Zhou, Jufang Gong, Tiejun Zhao i Zhigang Jin. "Development of FRET and Stress Granule Dual-Based System to Screen for Viral 3C Protease Inhibitors". Molecules 28, nr 7 (28.03.2023): 3020. http://dx.doi.org/10.3390/molecules28073020.
Pełny tekst źródłaSanachai, Kamonpan, Tuanjai Somboon, Patcharin Wilasluck, Peerapon Deetanya, Peter Wolschann, Thierry Langer, Vannajan Sanghiran Lee, Kittikhun Wangkanont, Thanyada Rungrotmongkol i Supot Hannongbua. "Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening". PLOS ONE 17, nr 6 (30.06.2022): e0269563. http://dx.doi.org/10.1371/journal.pone.0269563.
Pełny tekst źródłaGlab-ampai, Kittirat, Kanasap Kaewchim, Thanatsaran Saenlom, Watayagorn Thepsawat, Kodchakorn Mahasongkram, Nitat Sookrung, Wanpen Chaicumpa i Monrat Chulanetra. "Human Superantibodies to 3CLpro Inhibit Replication of SARS-CoV-2 across Variants". International Journal of Molecular Sciences 23, nr 12 (13.06.2022): 6587. http://dx.doi.org/10.3390/ijms23126587.
Pełny tekst źródłaYe, Gang, Xiaowei Wang, Xiaohan Tong, Yuejun Shi, Zhen F. Fu i Guiqing Peng. "Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376". Viruses 12, nr 2 (21.02.2020): 240. http://dx.doi.org/10.3390/v12020240.
Pełny tekst źródłaChen, Chia-Nan, Coney P. C. Lin, Kuo-Kuei Huang, Wei-Cheng Chen, Hsin-Pang Hsieh, Po-Huang Liang i John T. A. Hsu. "Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)". Evidence-Based Complementary and Alternative Medicine 2, nr 2 (2005): 209–15. http://dx.doi.org/10.1093/ecam/neh081.
Pełny tekst źródłaRana, Shiwani, Prateek Kumar, Anchal Sharma, Sanjay Sharma, Rajanish Giri i Kalyan S. Ghosh. "Identification of Naturally Occurring Antiviral Molecules for SARS-CoV-2 Mitigation". Open COVID Journal 1, nr 1 (10.06.2021): 38–46. http://dx.doi.org/10.2174/2666958702101010038.
Pełny tekst źródłaWu, Jing, Bo Feng, Li-Xin Gao, Chun Zhang, Jia Li, Da-Jun Xiang, Yi Zang i Wen-Long Wang. "Synthesis and Biochemical Evaluation of 8H-Indeno[1,2-d]thiazole Derivatives as Novel SARS-CoV-2 3CL Protease Inhibitors". Molecules 27, nr 10 (23.05.2022): 3359. http://dx.doi.org/10.3390/molecules27103359.
Pełny tekst źródłaRozprawy doktorskie na temat "3CLpro"
Brier, Lucile. "Conception d'une stratégie de découverte de composés antiviraux contre les coronavirus : du criblage à l'optimisation d'inhibiteurs de la protéase 3CL du SARS-CoV-2". Electronic Thesis or Diss., Université de Lille (2022-....), 2022. http://www.theses.fr/2022ULILS031.
Pełny tekst źródłaCoronaviruses are RNA viruses causing respiratory, enteric, hepatic and neurological diseases of varying severity in different species, including humans. Among them, seven can infect humans. HCoV-OC43, HCoV-NL63, HCoV-229E, and HCoV-HKU1 strains cause mild respiratory tract infections. SARS-CoV, MERS-CoV, and SARS-CoV-2 are potentially fatal and have caused major outbreaks. Today, SARS-CoV-2 is still circulating but the vaccine strategy has significantly reduced the risks of hospitalization and death. Also, the first specific antiviral drug has been authorized on the market (Paxlovid™). Nevertheless, coronaviruses are viruses with a high mutation and recombination rate, therefore the probability of facing new epidemics is very high. Thus, there is a need to discover new therapies to treat COVID-19 but also to anticipate and prevent future epidemics. Thanks to its essential role in the viral replication cycle of coronaviruses and the lack of human homolog, the viral protease 3CL is a promising target for the development of anti-coronaviral compounds. Moreover, this protease is remarkably conserved among coronavirus species. The 3CLpro is then an interesting target for the design of broad-spectrum antivirals able to fight against SARS-CoV-2 but also against potential emerging coronaviruses. Thus, the objective of this thesis work was to develop a strategy to discover new non-peptidomimetic inhibitors of the 3CLpro of SARS-CoV-2 that are potent, selective and capable of exerting pan-inhibition on other coronavirus species. The first part of this thesis project consisted of developing and performing a high-throughput screening on the SARS-CoV-2 3CL protease, allowing the identification of several chemical series of interest. Further work focused on the optimization of two chemical series, reversible covalent inhibitors for the first one and non-covalent for the second one, whose chemotypes have not been described on the 3CL protease. In these two chemical series, more than 90 analogues have been synthesized with the aim of improving the potency on the target and establishing structure-activity relationships. Physicochemical and ADME properties in vitro, binding mode, selectivity towards human proteases, inhibition of 3CLpro from other coronaviruses and in cellulo antiviral activity were studied
Części książek na temat "3CLpro"
Zhang, Jiapu. "3C-Like Protease (3CLpro)". W Springer Series in Biophysics, 33–159. Cham: Springer Nature Switzerland, 2023. http://dx.doi.org/10.1007/978-3-031-36773-1_2.
Pełny tekst źródłaZhang, Jiapu. "3CLpro Binding with N3/Lopinavir/Ritonavir". W Springer Series in Biophysics, 457–77. Cham: Springer Nature Switzerland, 2023. http://dx.doi.org/10.1007/978-3-031-36773-1_15.
Pełny tekst źródłaSims, A. C., X. T. Lu i M. R. Denison. "Expression, Purification, and Activity of Recombinant MHV-A59 3CLpro". W Advances in Experimental Medicine and Biology, 129–34. Boston, MA: Springer US, 1998. http://dx.doi.org/10.1007/978-1-4615-5331-1_17.
Pełny tekst źródłaZhang, Jiapu. "3CLpro Dimer Binding with 7 HIV Inhibitors and Others". W Springer Series in Biophysics, 479–509. Cham: Springer Nature Switzerland, 2023. http://dx.doi.org/10.1007/978-3-031-36773-1_16.
Pełny tekst źródłaHamill, Pamela, Martin Richer, Derek Hudson, Hongyan Xu i François Jean. "Novel Blue- and Red-Shifted Internally Quenched Fluorogenic Substrates for Continuous Monitoring of SARS-CoV 3CLpro". W Understanding Biology Using Peptides, 403–4. New York, NY: Springer New York, 2006. http://dx.doi.org/10.1007/978-0-387-26575-9_167.
Pełny tekst źródłaJayakumar, Manju Nidagodu, Jisha Pillai U., Moksha Mehta, Karanveer Singh, Eldhose Iype i Mainak Dutta. "Identification of Potential Inhibitors Against SARS-CoV-2 3CLpro, PLpro, and RdRP Proteins: An In-Silico Approach". W Advances in Computational Modeling and Simulation, 85–112. Singapore: Springer Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-7857-8_8.
Pełny tekst źródła"Peptidomimetic and Peptide-Derived Against 3CLpro from Coronaviruses". W Pharmaceuticals for Targeting Coronaviruses, redaktorzy Paulo Fernando da Silva Santos-Júnior, João Xavier de Araújo-Júnior i Edeildo Ferreira da Silva-Júnior, 158–88. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9789815051308122010007.
Pełny tekst źródłaHosseini, Fatemeh, Mehrdad Azin, Hamideh Ofoghi i Tahereh Alinejad. "Evaluation of Drug Repositioning by Molecular Docking of Pharmaceutical Resources to Identification of Potential SARS-CoV-2 Viral Inhibitors". W Drug Repurposing - Molecular Aspects and Therapeutic Applications [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.101395.
Pełny tekst źródłaRamos Tayt-Sohn, Victória. "Preparação in silico do alvo molecular 3Clpro do SARS-CoV-2". W Ciência Brasileira: Múltiplos olhares - Medicina, Saúde e Prevenção Volume 02. Wyd. 2. Brasil: Even3 Publicações, 2023. http://dx.doi.org/10.29327/cb-medicina-saude-e-prevencao-2.599858.
Pełny tekst źródłaTorawane, Sarika Daulatrao, i Sarika Torwane. "Therapeutic Potential of Medicinal Plants in the Management and Treatment of Severe Acute Respiratory Syndrome 2 (SARS CoV-2 [COVID-19])". W Exploring Complementary and Alternative Medicinal Products in Disease Therapy, 225–67. IGI Global, 2023. http://dx.doi.org/10.4018/978-1-7998-4120-3.ch010.
Pełny tekst źródłaStreszczenia konferencji na temat "3CLpro"
Mondal, Kushal, i Sowmya Kamath S. "QSAR Classification Models for Predicting 3CLPro-protease Inhibitor Activity". W 2021 IEEE 4th International Conference on Computing, Power and Communication Technologies (GUCON). IEEE, 2021. http://dx.doi.org/10.1109/gucon50781.2021.9573896.
Pełny tekst źródłaФомина, А. Д., i Д. И. Осолодкин. "РАЗРАБОТКА МЕТОДА АНСАМБЛЕВОГО ДОКИНГА ИНГИБИТОРОВ ПРОТЕАЗЫ 3CLPRO SARS-COV-2". W MedChem-Russia 2021. 5-я Российская конференция по медицинской химии с международным участием «МедХим-Россия 2021». Издательство Волгоградского государственного медицинского университета, 2021. http://dx.doi.org/10.19163/medchemrussia2021-2021-322.
Pełny tekst źródłaLin, Xiaoli, Xuan Liu i Xiaolong Zhang. "Anti-3CLpro Molecular Design Based on the Model Constrained by Specific DTIs". W 2023 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2023. http://dx.doi.org/10.1109/bibm58861.2023.10385660.
Pełny tekst źródłaSemenov, V. A., i L. B. Krivdin. "BENCHMARK CALCULATIONS OF 1H AND 13C NMR CHEMICAL SHIFTS IN THE SERIES OF NATURAL CANDIDATES AGAINST 3CLPRO OF SARS COV-2". W MedChem-Russia 2021. 5-я Российская конференция по медицинской химии с международным участием «МедХим-Россия 2021». Издательство Волгоградского государственного медицинского университета, 2021. http://dx.doi.org/10.19163/medchemrussia2021-2021-435.
Pełny tekst źródłaLan, Yuhao. "A Comparative Study of the Inhibitory Effects of Rheum palmatum L. and Isatis Indigotica Root, on 3CLpro from SARS-CoV-2 Using Both Cell-based and Cell-free Assay Models". W ICBET '21: 2021 11th International Conference on Biomedical Engineering and Technology. New York, NY, USA: ACM, 2021. http://dx.doi.org/10.1145/3460238.3461671.
Pełny tekst źródła